NextCure, Inc. Common Stock (NXTC)

Price$3.38

Value ScoreA

Momentum ScoreD

Favorite Metrics

Price vs S&P 500 (26W)-48.61%

Price vs S&P 500 (4W)-38.73%

VGM Score56.32

Market Capitalization$22.39M

All Metrics

Book Value / Share (Quarterly)$7.41

P/TBV (Annual)0.21x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-13.85

Price vs S&P 500 (YTD)-67.24%

Net Profit Margin (TTM)-65.22%

EPS (TTM)$-18.75

10-Day Avg Trading Volume0.05M

EPS Excl Extra (TTM)$-18.75

EPS (Annual)$-2.00

ROI (Annual)-85.53%

Net Profit Margin (5Y Avg)-825.97%

Cash / Share (Quarterly)$8.24

ROA (Last FY)-69.26%

EBITD / Share (TTM)$-15.23

ROE (5Y Avg)-45.43%

Operating Margin (TTM)-82.06%

Cash Flow / Share (Annual)$-14.15

P/B Ratio0.84x

P/B Ratio (Quarterly)1.42x

Net Income / Employee (Annual)$-1,400,000

EV / Revenue (TTM)0.26x

ROA (TTM)-124.62%

EPS Incl Extra (Annual)$-2.00

Current Ratio (Annual)4.14x

Quick Ratio (Quarterly)4.32x

3-Month Avg Trading Volume0.05M

52-Week Price Return4.03%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$4.54

P/S Ratio (Annual)1.00x

Asset Turnover (Annual)0.07x

52-Week High$15.74

Operating Margin (5Y Avg)-865.37%

EPS Excl Extra (Annual)$-2.00

CapEx CAGR (5Y)-32.45%

Tangible BV CAGR (5Y)60.79%

26-Week Price Return-32.68%

Quick Ratio (Annual)3.96x

13-Week Price Return-52.31%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)4.61x

Enterprise Value$7.23M

Asset Turnover (TTM)0.10x

Book Value / Share Growth (5Y)-1.30%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-163.54%

Cash / Share (Annual)$11.93

3-Month Return Std Dev103.05%

Net Income / Employee (TTM)$-1,366,600

ROE (Last FY)-85.53%

EPS Basic Excl Extra (Annual)$-2.00

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-18.75

ROI (TTM)-186.96%

P/S Ratio (TTM)0.82x

Pretax Margin (5Y Avg)-825.97%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$6.03

Price vs S&P 500 (52W)-24.18%

Year-to-Date Return-56.31%

5-Day Price Return-20.82%

EPS Normalized (Annual)$-2.00

ROA (5Y Avg)-39.88%

Net Profit Margin (Annual)-163.54%

Month-to-Date Return-32.68%

Cash Flow / Share (TTM)$-2.22

EBITD / Share (Annual)$-2.04

Operating Margin (Annual)-184.23%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-45.40%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-18.75

P/TBV (Quarterly)0.28x

P/B Ratio (Annual)1.42x

Pretax Margin (TTM)-65.22%

Book Value / Share (Annual)$9.97

Price vs S&P 500 (13W)-62.05%

Beta1.31x

P/FCF (Annual)4.54x

Revenue / Share (TTM)$0.00

ROE (TTM)-186.96%

52-Week Low$4.60

vGradeA

mGradeD

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-1.87est. -2.15

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.22

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
NXTCNextCure, Inc. Common Stock	A	—	D	$3.38
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
NVONovo-Nordisk A/S	B	B	C	$44.07
PFEPfizer Inc.	B	C	C	$25.63
ABTAbbott Laboratories	C	C	D	$87.78
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64

About

NextCure is a clinical-stage biopharmaceutical company developing immunomedicines to restore immune function in cancer and immune-related diseases. Its lead candidate, NC410, a LAIR-2 fusion protein, demonstrated early clinical activity in colorectal and ovarian cancers in combination with pembrolizumab, while LNCB74, an antibody-drug conjugate targeting B7-H4, is also in clinical development. The company is seeking strategic partners for additional clinical programs including NC525 and NC318, as well as preclinical candidates in chronic bone diseases and neurological indications.